Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Brenda L. Stevens"'
Autor:
Damion Winship, Ray Carrillo, Brenda L. Stevens, Jonathan Grey, Hengyu Xu, Ben Setter, Robert F. Dubose, Peter R. Baum, Jenny C. Chang, Heather Metz, Li-Qun Fan, Ty Brender, Jeffrey Adamo, Sean W. Smith, Jamie Brevik, Yvette Latchman, Michael R. Comeau, Monica Childs, Phil Tan, Valerie Odegard
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background SBT6290 is a novel therapeutic comprised of a selective TLR8 agonist conjugated to a Nectin-4-specific monoclonal antibody, designed for systemic delivery and tumor-localized activation of myeloid cells. Nectin-4 is a cell surface adhesion
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::194826442d9255b60ef94c5300b86ac5
https://doi.org/10.1136/jitc-2020-sitc2020.0712
https://doi.org/10.1136/jitc-2020-sitc2020.0712
Autor:
Michael R. Comeau, Ben Setter, Marcus Rhodehamel, Brenda L. Stevens, Valerie Odegard, Monica Childs, Jamie Brevik, Jenny C. Chang, Yvette Latchman, Damion Winship, Ray Carillo, Elsa Hay, Jeffrey Adamo, Phil Tan, Hengyu Xu, Peter R. Baum, Jonathan Grey, Robert F. Dubose, Li-Qun Fan, Sean W. Smith, Heather E. Metz
Publikováno v:
Cancer Research. 81:1858-1858
SBT6290 is a novel product candidate comprised of a selective TLR8 agonist conjugated to a Nectin4-specific monoclonal antibody, designed for systemic delivery and tumor-localized activation of myeloid cells. Nectin4 is a cell surface adhesion molecu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e5ebdef92657cf84b1aa93dc05247e7
https://doi.org/10.1158/1538-7445.am2021-1858
https://doi.org/10.1158/1538-7445.am2021-1858
Autor:
Sean W. Smith, Hengyu Xu, Peter R. Baum, Yvette Latchman, Jamie Brevik, Ty Brender, Phil Tan, Jeffrey Adamo, Valerie Odegard, Michael R. Comeau, Li-Qun Fan, Monica Childs, Jenny C. Chang, Ben Setter, Robert F. Dubose, Damion Winship, Heather Metz, Brenda L. Stevens
Publikováno v:
Cancer Research. 80:4537-4537
SBT6050, a novel therapeutic comprised of a potent toll-like receptor (TLR) 8 agonist conjugated to a HER2-directed monoclonal antibody that binds an epitope distinct from trastuzumab, is designed for systemic delivery and tumor-localized activation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb16e44c349c30e8b5c3dabbc5022481
https://doi.org/10.1158/1538-7445.am2020-4537
https://doi.org/10.1158/1538-7445.am2020-4537
Autor:
Nels B. Hamacher, Megan M. Lantry, Pallavur V. Sivakumar, Robert Rosler, Brenda L. Stevens, Secil Franke, Craig D. Ostrander, Debra G. Gilbertson, Penny Thompson, Mark Snavely, Cindy Yen, Tom Bukowski, Anitra Wolf, Hank Franklin, Robert Mabry, Dan Ardourel, Kenneth Brasel, Scott R. Presnell, Qi Pan, Julien Susan H, Michael G. Dodds, Amanda Frank, Scott Peterson, Tuyen Vu, Monica Anderson-Haley, Brent Meengs, Sara Underwood, Jennifer A. Brody
Publikováno v:
mAbs. 2:20-34
Targeting angiogenesis is a promising approach to the treatment of solid tumors and age-related macular degeneration (AMD). Inhibition of vascularization has been validated by the successful marketing of monoclonal antibodies (mAbs) that target speci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc5661385a95b8994d0b6f369e357c8c
https://doi.org/10.4161/mabs.2.1.10498
https://doi.org/10.4161/mabs.2.1.10498
Autor:
Amanda Frank, Jennifer A. Brody, Ty Brender, Mark W. Appleby, Thomas R. Bukowski, Tuyen Vu, Kristen Bontadelli, Brian Reardon, Dan Ardourel, Luann Lockwood, Robert Mabry, Margaret D. Moore, Karen Lum, Brent Meengs, Patsy Lewis, Craig D. Ostrander, Nels B. Hamacher, Megan M. Lantry, Mark Snavely, Joseph L. Kuijper, Julien Susan H, James W. West, Brenda L. Stevens, Kenneth B. Lewis, Steven D. Levin, Kelly Byrnes-Blake, Chung Chan, Scott R. Presnell, Anitra Wolf, Okada Shannon L, Secil Franke, Debra G. Gilbertson, Katherine E. Lewis, Patricia A. Mckernan
Publikováno v:
Protein engineering, designselection : PEDS. 23(3)
Bispecific antibodies (bsAbs) present an attractive opportunity to combine the additive and potentially synergistic effects exhibited by combinations of monoclonal antibodies (mAbs). Current challenges for engineering bsAbs include retention of the b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05481693612d2d61e29505fd2e53305d
https://pubmed.ncbi.nlm.nih.gov/20022918
https://pubmed.ncbi.nlm.nih.gov/20022918